drugset
drugset / Trial / NCT03829241

Randomized Trial of Adult Participants With Generalized Anxiety Disorder

NCT03829241 ↗

Phase 3 Completed 881 enrolled Biohaven Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.

Timeline

Start
2019-02-19
Primary completion
2020-01-14
Completion
2020-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Troriluzole Peptide 100 mg Oral

Indications

generalized anxiety disorder